AFX Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Carl Zeiss Meditec (ETR: AFX)
›
Carl Zeiss Meditec (ETR: AFX) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 5,784 employees.
The shares were at 32.26 EUR on 19 November 2026, down 20.3% over 52 weeks. Its 52-week range is 22.62 EUR to 46.54 EUR: the price is 30.7% below the high and 42.6% above the low.
At a market capitalisation of 2.82B EUR, it trades at 23.2 times trailing earnings and 22.1 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 53% for AFX. It pays a dividend yielding 1.60% (it pays out 40% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Carl Zeiss Meditec reports return on equity of 6.7%, an operating margin of 7.2% and revenue up 2.4% year over year.
Its debt exceeds its cash by 557.06M EUR, a debt-to-equity ratio of 0.06. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 15 analysts cover the stock, with an average rating of Underperform; their mean price target of 26.86 EUR is 16.7% below the current price. The next earnings report is expected on 10 December 2026.